HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of bovine pericardial tissue for aortic valve and aortic root replacement: long-term results.

AbstractBACKGROUND AND AIMS OF THE STUDY:
The study aimed to determine the clinical performance of bovine pericardial aldehyde-treated products alone or in combination with aortic leaflets of porcine origin. These included a composite porcine stentless aortic valve attached to a scalloped pericardial tube (BSAV), and valved and non-valved bovine pericardial conduits for use in left-sided heart lesions (BPG).
METHODS:
For BSAV grafts, between January 1990 and August 1996, 163 patients (119 males) had their aortic valves replaced by SJM Biocor BASV. Mean age was 37.9 +/- 17.6 years (range: 1 to 76 years). Rheumatic heart disease sequelae (n = 72) and replacement of a prosthetic heart valve (n = 46) were predominant. Preoperative NYHA functional class showed 90 patients (55.2%) in class III and 50 (30.7%) in class IV. BPVC and NVPC grafts were used in 166 patients: acute aortic dissection was the main indication in 52 (31.3%) and chronic in 36 (21/7%). The ascending aorta was involved in 141 patients (84.9%); grafts were seldom used at other sites. In most patients the graft implanted was either a non-valved (n = 79) or a valved (n = 75) pericardial conduit. Twelve patients had a localized lesion and required a patch repair.
RESULTS:
For BASV grafts, the non-valve-related hospital mortality rate was 4.9%. There were 14.7% non-fatal complications with full recovery of all patients. Mean follow up in 141 patients was 3.0 +/- 1.4 years (range: 1 month to 7.2 years); 14 patients were lost to follow up. Late, non-conduit-related, mortality occurred in seven patients (4.9%). Eight patients underwent reoperation. The current clinical follow up of 127 patients has shown 118 (92.9%) with competent valves and nine (7.0%) with mild stable aortic insufficiency. For BPVC and NVPC grafts, hospital mortality rate was 16.9%, death being related to poor preoperative clinical condition. Postoperative follow up was accomplished in 125 patients; reoperation was necessary in seven patients. Histology showed good tissue preservation up to five years; echocardiography revealed satisfactory findings. No valved conduit had to be reoperated for valve or pericardial tissue wear.
CONCLUSIONS:
Clinical results of left-sided heterologous pericardial grafts have shown excellent performance over time. The BASV (over seven years) and BPVC and NVPC (eight years) have demonstrated superior results as aortic valves alone or in combination with a pericardial conduit.
AuthorsM Vrandecic, B Gontijo Filho, F Fantini, J Barbosa, I Martins, O C de Oliveira, C Martins, R Max, L Drumond, C Oliveira, A Ferrufino, E Alcocer, J A Silva, E Vrandecic
JournalThe Journal of heart valve disease (J Heart Valve Dis) Vol. 7 Issue 2 Pg. 195-201 (Mar 1998) ISSN: 0966-8519 [Print] England
PMID9587861 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Aldehydes
Topics
  • Adolescent
  • Adult
  • Aged
  • Aldehydes
  • Animals
  • Aorta (surgery)
  • Aorta, Thoracic (surgery)
  • Aortic Valve (diagnostic imaging, surgery)
  • Bioprosthesis (adverse effects)
  • Blood Vessel Prosthesis
  • Cattle
  • Child
  • Child, Preschool
  • Echocardiography, Doppler
  • Evaluation Studies as Topic
  • Female
  • Follow-Up Studies
  • Heart Valve Prosthesis (adverse effects)
  • Heart Valve Prosthesis Implantation (methods, mortality)
  • Humans
  • Male
  • Middle Aged
  • Pericardium (transplantation)
  • Prosthesis Design
  • Prosthesis Failure
  • Reoperation
  • Retrospective Studies
  • Rheumatic Heart Disease (diagnosis, mortality, surgery)
  • Survival Rate
  • Tissue Preservation (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: